Clinical Trial Update: Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response [Phase 1]

View source ↗

Summary

This Phase 1 trial of Sunitinib in metastatic renal cell carcinoma evaluated imaging biomarkers to predict early tumor response during therapy and reported the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Sunitinib (sunitinib)

Snippet

Sponsor: University of Utah | Conditions: Renal Cell Cancer | Phase 1 | Status: COMPLETED | Results posted: 2015-12-01